CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 145 enrolled
Drug / intervention
Escitalopram +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07074652
NCT07074652N/ACompleted

The Effect of SSRIs on Threat of Shock Potentiated Neural Circuitry

UCLH/UCL Joint Research Office·interventional·Posted Jul 20, 2025·Updated Jul 20, 2025

In Brief

A clinical study evaluating Escitalopram and Placebo for Anxiety. Completed, enrolled 145 participants across 1 site.

Detailed Summary

This study aims to increase the knowledge about psychological processes which may contribute to mental health problems such as depression and anxiety. This study aims to investigate if administering Escitalopram, an antidepressant which increases serotonin levels in parts of the brain, affects how the brain processes emotional information. It is hoped that measuring these changes will increase the understanding of processes involved in mental health problems.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnxiety
CountriesUnited Kingdom

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedJul 20, 2025
Enrollment StartDec 1, 2017
Primary CompletionJun 30, 2022
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 11 months ago

Interventions

Escitalopramdrug

Participants received 2-3 weeks of escitalopram.

Placebodrug

Participants received 2-3 weeks of placebo, matched in colour and size to the escitalopram.